This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Grégory Michel
Université Côte d’Azur, Inserm, U1065, C3M, Nice
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Leishmania infantum is the causative agent of visceral leishmaniasis transmitted by the bite of female sand flies. According to the WHO, the estimated annual incidence of leishmaniasis is one million new cases, resulting in 30 000 deaths per year. The recommended drugs for treating leishmaniasis include Amphotericin B. But over the course of the years, several cases of relapses have been documented. These relapses cast doubt on the efficiency of actual treatments and raise the question of potential persistence sites. Indeed, Leishmania has the ability to persist in humans for long periods of time and even after successful treatment. Several potential persistence sites have already been identified and named ‘safe targets’. As adipose tissue has been proposed as a sanctuary of persistence for several pathogens, we investigated whether Leishmania infantum could be found in this tissue. We demonstrated both in cell cultures and in vivo that Leishmania infantum was able to infect adipocytes. Altogether our results suggest adipocytes as a ‘safe target’ for Leishmania infantum parasites.
Keywords
Leishmania infantum, parasites, leishmaniasis
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
No competing interests reported.
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 12 Mar, 2021
No community comments so far
Editorial decision: Major revision
On 24 Mar, 2021
Review #3 received
Received 23 Mar, 2021
Review #1 received
Received 23 Mar, 2021
Review #2 received
Received 23 Mar, 2021
Reviewer #2 agreed
On 18 Mar, 2021
Reviewer #6 agreed
On 18 Mar, 2021
Reviewer #4 agreed
On 18 Mar, 2021
Reviewer #3 agreed
On 18 Mar, 2021
Reviewer #5 agreed
On 18 Mar, 2021
Reviewer #1 agreed
On 18 Mar, 2021
Reviewers invited
Invitations sent on 12 Mar, 2021
Editor assigned
On 11 Mar, 2021
Editor invited
On 11 Mar, 2021
Submission checks complete
On 11 Mar, 2021
First submitted
On 01 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Grégory Michel
Université Côte d’Azur, Inserm, U1065, C3M, Nice
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 12 Mar, 2021
No community comments so far
Editorial decision: Major revision
On 24 Mar, 2021
Review #3 received
Received 23 Mar, 2021
Review #1 received
Received 23 Mar, 2021
Review #2 received
Received 23 Mar, 2021
Reviewer #2 agreed
On 18 Mar, 2021
Reviewer #6 agreed
On 18 Mar, 2021
Reviewer #4 agreed
On 18 Mar, 2021
Reviewer #3 agreed
On 18 Mar, 2021
Reviewer #5 agreed
On 18 Mar, 2021
Reviewer #1 agreed
On 18 Mar, 2021
Reviewers invited
Invitations sent on 12 Mar, 2021
Editor assigned
On 11 Mar, 2021
Editor invited
On 11 Mar, 2021
Submission checks complete
On 11 Mar, 2021
First submitted
On 01 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Leishmania infantum is the causative agent of visceral leishmaniasis transmitted by the bite of female sand flies. According to the WHO, the estimated annual incidence of leishmaniasis is one million new cases, resulting in 30 000 deaths per year. The recommended drugs for treating leishmaniasis include Amphotericin B. But over the course of the years, several cases of relapses have been documented. These relapses cast doubt on the efficiency of actual treatments and raise the question of potential persistence sites. Indeed, Leishmania has the ability to persist in humans for long periods of time and even after successful treatment. Several potential persistence sites have already been identified and named ‘safe targets’. As adipose tissue has been proposed as a sanctuary of persistence for several pathogens, we investigated whether Leishmania infantum could be found in this tissue. We demonstrated both in cell cultures and in vivo that Leishmania infantum was able to infect adipocytes. Altogether our results suggest adipocytes as a ‘safe target’ for Leishmania infantum parasites.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Loading...